URN:NBN:SI:DOC-VRFJ0DLK2025Klen, JasnaTonin, Gašperdocuments/doc/V/URN_NBN_SI_doc-VRFJ0DLK_001.pdfdocuments/doc/V/URN_NBN_SI_doc-VRFJ0DLK_001.txt464articlestr. 453-4640025-8121266146563URN:NBN:SI:doc-VRFJ0DLKslvMedicinski razglediMedicinski razglediInCdebelostfarmakogenetikagenetic polymorphismgenetski polimorfizemincretinsinkretiniobesitypharmacogenomicssladkorna bolezen tipa 2type 2 diabetes mellitusSladkorna bolezen tipa 2 – vloga genetskih polimorfizmov pri odzivu na zdravljenje z zaviralci natrij-glukoznega koprenašalca 2 ter agonisti receptorja za glukagonu podobni peptid 1Type 2 diabetes and obesity – the role of genetic polymorphisms in the response to treatment with sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists